, NR 565 Advanced Pharmacology Exam
V3 (2026/2027) Questions with Answers
& Detailed Rationales
Question 1
A 64-year-old patient with type 2 diabetes and stable coronary
artery disease is evaluated for cardioprotective glucose-lowering
therapy. Which class of medications has demonstrated
significant reductions in heart failure hospitalizations and major
adverse cardiovascular events independent of glycemic control?
A) Sulfonylureas
B) Sodium-glucose cotransporter 2 inhibitors
C) Dipeptidyl peptidase-4 inhibitors
D) Meglitinides
Correct Answer: B) Sodium-glucose cotransporter 2
inhibitors
Rationale: Sodium-glucose cotransporter 2 inhibitors provide
robust cardiorenal protection, significantly reducing heart failure
hospitalizations and slowing the progression of chronic kidney
disease in patients with or without type 2 diabetes.
Question 2
An APRN is prescribing a newly approved direct oral
anticoagulant for a patient with non-valvular atrial fibrillation.
,Which laboratory parameter must be evaluated at baseline and
periodically monitored to ensure safe drug elimination?
A) Complete blood count and hemoglobin levels
B) Renal function panels including serum creatinine and
estimated glomerular filtration rate
C) Liver transaminases and baseline coagulation profiles
D) Serum electrolyte panels focusing exclusively on serum
sodium
Correct Answer: B) Renal function panels including serum
creatinine and estimated glomerular filtration rate
Rationale: Direct oral anticoagulants rely heavily on renal
clearance for elimination. Baseline and ongoing assessment of
renal function is mandatory to adjust dosages and prevent drug
accumulation and major bleeding complications.
Question 3
A patient with major depressive disorder is prescribed
escitalopram. What is the primary molecular mechanism of
action of selective serotonin reuptake inhibitors?
A) Direct stimulation of post-synaptic serotonin receptors in
the limbic system
B) Selective inhibition of the presynaptic serotonin reuptake
transporter protein
, C) Irreversible blockade of monoamine oxidase enzymes in
central neurons
D) Antagonism of central alpha-2 adrenergic receptors on
nerve terminals
Correct Answer: B) Selective inhibition of the presynaptic
serotonin reuptake transporter protein
Rationale: Selective serotonin reuptake inhibitors block the
presynaptic serotonin transporter, preventing the reabsorption of
serotonin into nerve terminals and increasing its concentration
within the synaptic cleft to enhance neurotransmission.
Question 4
A patient with chronic asthma is prescribed a leukotriene
receptor antagonist (montelukast). What is the primary
pharmacodynamic action of this medication?
A) Inhibition of mucosal mast cell degranulation and
histamine release
B) Competitive antagonism of cysteinyl leukotriene receptors
on airway smooth muscle
C) Direct stimulation of beta-2 adrenergic receptors to
promote bronchodilation
D) Inhibition of intracellular phosphodiesterase enzymes in
inflammatory cells
Correct Answer: B) Competitive antagonism of cysteinyl
leukotriene receptors on airway smooth muscle
V3 (2026/2027) Questions with Answers
& Detailed Rationales
Question 1
A 64-year-old patient with type 2 diabetes and stable coronary
artery disease is evaluated for cardioprotective glucose-lowering
therapy. Which class of medications has demonstrated
significant reductions in heart failure hospitalizations and major
adverse cardiovascular events independent of glycemic control?
A) Sulfonylureas
B) Sodium-glucose cotransporter 2 inhibitors
C) Dipeptidyl peptidase-4 inhibitors
D) Meglitinides
Correct Answer: B) Sodium-glucose cotransporter 2
inhibitors
Rationale: Sodium-glucose cotransporter 2 inhibitors provide
robust cardiorenal protection, significantly reducing heart failure
hospitalizations and slowing the progression of chronic kidney
disease in patients with or without type 2 diabetes.
Question 2
An APRN is prescribing a newly approved direct oral
anticoagulant for a patient with non-valvular atrial fibrillation.
,Which laboratory parameter must be evaluated at baseline and
periodically monitored to ensure safe drug elimination?
A) Complete blood count and hemoglobin levels
B) Renal function panels including serum creatinine and
estimated glomerular filtration rate
C) Liver transaminases and baseline coagulation profiles
D) Serum electrolyte panels focusing exclusively on serum
sodium
Correct Answer: B) Renal function panels including serum
creatinine and estimated glomerular filtration rate
Rationale: Direct oral anticoagulants rely heavily on renal
clearance for elimination. Baseline and ongoing assessment of
renal function is mandatory to adjust dosages and prevent drug
accumulation and major bleeding complications.
Question 3
A patient with major depressive disorder is prescribed
escitalopram. What is the primary molecular mechanism of
action of selective serotonin reuptake inhibitors?
A) Direct stimulation of post-synaptic serotonin receptors in
the limbic system
B) Selective inhibition of the presynaptic serotonin reuptake
transporter protein
, C) Irreversible blockade of monoamine oxidase enzymes in
central neurons
D) Antagonism of central alpha-2 adrenergic receptors on
nerve terminals
Correct Answer: B) Selective inhibition of the presynaptic
serotonin reuptake transporter protein
Rationale: Selective serotonin reuptake inhibitors block the
presynaptic serotonin transporter, preventing the reabsorption of
serotonin into nerve terminals and increasing its concentration
within the synaptic cleft to enhance neurotransmission.
Question 4
A patient with chronic asthma is prescribed a leukotriene
receptor antagonist (montelukast). What is the primary
pharmacodynamic action of this medication?
A) Inhibition of mucosal mast cell degranulation and
histamine release
B) Competitive antagonism of cysteinyl leukotriene receptors
on airway smooth muscle
C) Direct stimulation of beta-2 adrenergic receptors to
promote bronchodilation
D) Inhibition of intracellular phosphodiesterase enzymes in
inflammatory cells
Correct Answer: B) Competitive antagonism of cysteinyl
leukotriene receptors on airway smooth muscle
